The role of PCSK9 inhibitors as treatment for dyslipidemia now that statin therapies are available. Deepak L. Bhatt, MD, MPH: Speaking of PCSK9 inhibitors, let’s turn back to Dr Budoff. I was going to ...

CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial ...

In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...

Once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) therapy has moved into a new phase with Food and Drug ...

New York, USA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | ...

A draft report on the value-based price benchmark for the newly approved PCSK9 inhibitors for lowering bad cholesterol found that Repatha and Praluent should cost approximately 85% less than their ...

In 2015, when the first cholesterol-lowering drugs targeting a protein called PCSK9 were about to hit the market, anticipation in the cardiovascular community ran high. Elevated levels of low-density ...

Amgen made a splash a year ago with its announcement that it was cutting the list price of its PCSK9 cholesterol drug Repatha from $14,520 to $5,850—even though it maintained the pricier option for ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibition demonstrated benefit in the broader primary prevention population for LDL lowering and plaque ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...